RxDoctor Payments Data

Sarah Tremblay, APRN

Family · Amherst, NHNPI 1023776333

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 63 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$415
  • Novo Nordisk$227
  • Abbott$132
  • Lilly USA, LLC$105
  • Biohaven Pharmaceutical Holding Company Ltd.$61
  • Xeris Pharmaceuticals, Inc.$54
  • plus $192 from 8 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,187 in reported general payments places this provider in the 85th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$45,118
Medicare patients
95
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$165,855
OzempicSemaglutide119$123,984
TrulicityDulaglutide111$121,294
Humalog Kwikpen U-200Insulin Lispro23$49,244
MounjaroTirzepatide42$46,957
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$43,719
Tresiba Flextouch U-200Insulin Degludec24$41,283
Tresiba Flextouch U-100Insulin Degludec41$24,052
FarxigaDapagliflozin Propanediol11$13,744
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$12,089
Humalog Kwikpen U-100Insulin Lispro19$8,232
Nano 2nd Gen Pen NeedlePen Needle, Diabetic55$6,114
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,881
Insulin Lispro12$1,438
Rosuvastatin Calcium19$830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro$105$169,689165 claims
Novo NordiskOzempic$227$123,984119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 713 family providers in New Hampshire.

Other family in Amherst

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →